ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Completed · Phase 3

Conditions studied: Allergic Conjunctivitis

In brief

A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis

Key facts

Study ID
NCT03494504
Run by
Aldeyra Therapeutics, Inc.
People needed
318
Starts
2018-03-30
Expected to finish
2018-11-05
Last updated by the study team
2025-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.